Analy­sis: Pfiz­er tal­lies an im­pres­sive ar­ray of late-stage cat­a­lysts for can­cer, gene ther­a­pies and more

Pfiz­er ex­ecs ran through their 2018 late-stage pipeline plan on Tues­day, high­light­ing the key cat­a­lysts that await dur­ing their Q4 call with an­a­lysts. And can­cer drugs fig­ured promi­nent­ly in the dis­cus­sion.

We won’t have long to wait be­fore the news gets start­ed.

First up, the Phase III PROS­PER da­ta for Xtan­di, which is po­si­tion­ing it­self against J&J’s next-gen drug for Zyti­ga. Pfiz­er and its part­ners at Astel­las are anx­ious to get the FDA re­view un­der­way for non­metasta­t­ic prostate can­cer, which could add con­sid­er­ably to its fran­chise val­ue as gener­ics start to slice and dice the mar­ket for J&J’s ri­val ther­a­py Zyti­ga. J&J has a next-gen drug in late-stage de­vel­op­ment for non­metasta­t­ic prostate can­cer which is cru­cial to its near-term abil­i­ty to com­pete with Pfiz­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER